本文選題：絕經(jīng)后骨質(zhì)疏松 + 骨松寶顆粒　； 參考：《廣州中醫(yī)藥大學(xué)》2017年碩士論文

【摘要】：目的:研究觀察骨松寶顆粒對絕經(jīng)后骨質(zhì)疏松(Postmenopausal osteoporosis,PMOP)患者不同時間段骨轉(zhuǎn)換標(biāo)志物水平的影響及對骨密度的改善情況。方法:本次試驗研究對象為:2015年9月至2016年6月在廣州中醫(yī)藥大學(xué)第二附屬醫(yī)院骨傷二科診斷為絕經(jīng)后骨質(zhì)疏松的患者。對符合納入標(biāo)準(zhǔn)的研究對象隨機分為試驗組(骨松寶組)及對照組(唑來膦酸組)。所有研究對象均予每日口服鈣爾奇(1粒、qd)及羅蓋全(1粒、qd)作為基礎(chǔ)治療。試驗組患者入組后一年內(nèi)口服骨松寶顆粒(1袋、bid),對照組患者住院期間予靜滴唑來膦酸0.5g(靜滴前后均靜滴0.9%氯化鈉溶液500ml)。對比骨松寶組及唑來膦酸組治療前與治療后3個月、6個月的鈣離子、Ⅰ型膠原氨基端延長肽(PINP)、骨鈣素N端片段(N-MID)、Ⅰ型膠原羧基端肽β特殊序列(β-CTX)、25羥基維生素D(25-(OH)-D),以及治療后1年的骨密度(bone mineral density,BMD),記錄兩組患者腰部、髖部、腕部等部位骨質(zhì)疏松性骨折的發(fā)生人數(shù)。結(jié)果:本研究共納入60例(骨松寶組30例,唑來膦酸組30例)女性患者,平均年齡為65.47±9.83歲。對比骨松寶組及唑來膦酸組納入研究對象的人口學(xué)資料、治療前鈣離子、維生素D、肌酐、肌酐清除率、骨代謝三項(包括PINP、β-CTX、N-MID)、腰椎及左側(cè)股骨頸T-score,基線均衡(P0.05)。骨松寶組中治療前β-CTX、N-MID水平與治療后3個月對比無統(tǒng)計學(xué)差異,治療前鈣離子、維生素D、PINP水平與治療后3個月對比具有統(tǒng)計學(xué)差異(P0.05);骨松寶組治療前N-MID與治療后6個月對比無統(tǒng)計學(xué)差異,治療前鈣離子、維生素D、PINP、β-CTX水平與治療后6個月對比具有統(tǒng)計學(xué)差異(P0.05)。骨松寶組治療前腰椎、左側(cè)股骨頸T-score與治療后1年對比均具有統(tǒng)計學(xué)差異。唑來膦酸組治療前鈣離子、維生素D、PINP、N-MID與治療后3個月對比無統(tǒng)計學(xué)差異,治療前β-CTX與治療后3個月對比具有統(tǒng)計學(xué)差異(P0.05);治療前維生素D、PINP、N-MID與治療后6個月對比無統(tǒng)計學(xué)差異,治療前鈣離子、β-CTX與治療后6個月對比具有統(tǒng)計學(xué)差異(P0.05)。唑來膦酸組治療前左側(cè)股骨頸T-score與治療后1年對比無統(tǒng)計學(xué)差異,治療前腰椎T-score與治療后1年對比具有統(tǒng)計學(xué)差異(P0.05)。結(jié)論:骨松寶顆粒在短期內(nèi)能較好的升高絕經(jīng)后骨質(zhì)疏松患者骨形成指標(biāo),同時在增加骨密度方面的效果接近于唑來膦酸,可有效減低患者發(fā)生骨質(zhì)疏松性骨折的發(fā)生。
[Abstract]:Aim: to study the effect of Gusongbao granule on bone turnover markers and bone mineral density in postmenopausal osteoporosis patients with PMOP (postmenopausal osteoporosis). Methods: patients with postmenopausal osteoporosis were diagnosed in the second affiliated Hospital of Guangzhou University of traditional Chinese Medicine from September 2015 to June 2016. Subjects who met the inclusion criteria were randomly divided into experimental group (Gusongbao group) and control group (Zoledronic acid group). All of the subjects were treated with oral administration of QD (1 QD) and rogualone (1 QD) as basic treatment. The patients in the test group were given orally guzongbao granules and 1 bag of bidbidine in the first year after admission, while the patients in the control group were given 0.5 g of zoledronic acid (0.9% sodium chloride solution 500 ml / L before and after intravenous drip) while the patients in the control group were given intravenous drip of Zoledronic acid 0.5 g. The calcium ions before and after treatment were compared between the Gusongbao group and the zoledronic acid group. The amino terminal lengthening peptide of collagen type 鈪，

本文編號：1810365